These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 24175261)

  • 1. Uric acid and chronic kidney disease: A time to act?
    Bellomo G
    World J Nephrol; 2013 May; 2(2):17-25. PubMed ID: 24175261
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of serum uric acid reduction on renal function and blood pressure in chronic kidney disease patients with hyperuricemia.
    Tsuji T; Ohishi K; Takeda A; Goto D; Sato T; Ohashi N; Fujigaki Y; Kato A; Yasuda H
    Clin Exp Nephrol; 2018 Dec; 22(6):1300-1308. PubMed ID: 29700702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of efficacy and safety between febuxostat and allopurinol in early post-renal transplant recipients with new onset of hyperuricemia.
    Shen X; Li J; Fu Q; Liu L; Gao X; Chen X; Chen P; Wang C
    J Clin Pharm Ther; 2019 Apr; 44(2):318-326. PubMed ID: 30582178
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Uric acid and chronic kidney disease: which is chasing which?
    Johnson RJ; Nakagawa T; Jalal D; Sánchez-Lozada LG; Kang DH; Ritz E
    Nephrol Dial Transplant; 2013 Sep; 28(9):2221-8. PubMed ID: 23543594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of uric acid-lowering therapy on renal outcomes: a systematic review and meta-analysis.
    Bose B; Badve SV; Hiremath SS; Boudville N; Brown FG; Cass A; de Zoysa JR; Fassett RG; Faull R; Harris DC; Hawley CM; Kanellis J; Palmer SC; Perkovic V; Pascoe EM; Rangan GK; Walker RJ; Walters G; Johnson DW
    Nephrol Dial Transplant; 2014 Feb; 29(2):406-13. PubMed ID: 24042021
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Uric acid lowering therapies for preventing or delaying the progression of chronic kidney disease.
    Sampson AL; Singer RF; Walters GD
    Cochrane Database Syst Rev; 2017 Oct; 10(10):CD009460. PubMed ID: 29084343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Comorbidity in gout and hyperuricemia: prevalence, causes, prospects of urate lowering therapy].
    Eliseev MS; Novikova AM
    Ter Arkh; 2019 May; 91(5):120-128. PubMed ID: 32598686
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized controlled trial of febuxostat versus allopurinol or placebo in individuals with higher urinary uric acid excretion and calcium stones.
    Goldfarb DS; MacDonald PA; Gunawardhana L; Chefo S; McLean L
    Clin J Am Soc Nephrol; 2013 Nov; 8(11):1960-7. PubMed ID: 23929928
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of febuxostat in the treatment of hyperuricemia in stable kidney transplant recipients.
    Sofue T; Inui M; Hara T; Nishijima Y; Moriwaki K; Hayashida Y; Ueda N; Nishiyama A; Kakehi Y; Kohno M
    Drug Des Devel Ther; 2014; 8():245-53. PubMed ID: 24600205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Asymptomatic hyperuricemia following renal transplantation.
    Bellomo G
    World J Nephrol; 2015 Jul; 4(3):324-9. PubMed ID: 26167455
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Time to target uric acid to retard CKD progression.
    Kumagai T; Ota T; Tamura Y; Chang WX; Shibata S; Uchida S
    Clin Exp Nephrol; 2017 Apr; 21(2):182-192. PubMed ID: 27339448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of Drug Treatments for Lowering Uric Acid on Renal Function in Patients With Chronic Kidney Disease and Hyperuricemia: A Network Meta-Analysis of Randomized Controlled Trials.
    Liu X; Qiu Y; Li D; Tan J; Liang X; Qin W
    Front Pharmacol; 2021; 12():690557. PubMed ID: 34413775
    [No Abstract]   [Full Text] [Related]  

  • 13. Uric acid and progression of chronic kidney disease.
    Weaver DJ
    Pediatr Nephrol; 2019 May; 34(5):801-809. PubMed ID: 29931555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. As compared to allopurinol, urate-lowering therapy with febuxostat has superior effects on oxidative stress and pulse wave velocity in patients with severe chronic tophaceous gout.
    Tausche AK; Christoph M; Forkmann M; Richter U; Kopprasch S; Bielitz C; Aringer M; Wunderlich C
    Rheumatol Int; 2014 Jan; 34(1):101-9. PubMed ID: 24026528
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renal Effects of Hyperuricemia.
    Méndez Landa CE
    Contrib Nephrol; 2018; 192():8-16. PubMed ID: 29393089
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The urate-lowering efficacy and safety of febuxostat versus allopurinol in Chinese patients with asymptomatic hyperuricemia and with chronic kidney disease stages 3-5.
    Liu X; Wang H; Ma R; Shao L; Zhang W; Jiang W; Luo C; Zhai T; Xu Y
    Clin Exp Nephrol; 2019 Mar; 23(3):362-370. PubMed ID: 30291473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hyperuricemia has increased the risk of progression of chronic kidney disease: propensity score matching analysis from the KNOW-CKD study.
    Oh TR; Choi HS; Kim CS; Bae EH; Ma SK; Sung SA; Kim YS; Oh KH; Ahn C; Kim SW
    Sci Rep; 2019 Apr; 9(1):6681. PubMed ID: 31040373
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Hyperuricaemia and Chronic Kidney Disease].
    Garofalo C; De Stefano T; Vita C; Vinci G; Balia F; Nettuno F; Scarpati L; Sguazzo A; Sagliocchi A; Pacilio M; Minutolo R; De Nicola L; Borrelli S
    G Ital Nefrol; 2018 Feb; 35(1):. PubMed ID: 29390240
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level.
    Siu YP; Leung KT; Tong MK; Kwan TH
    Am J Kidney Dis; 2006 Jan; 47(1):51-9. PubMed ID: 16377385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The uric acid cardio-nephropathy].
    Viazzi F; Bonino B; Cappadona F; Pontremoli R
    G Ital Nefrol; 2017 Mar; 34(Suppl 69):41-48. PubMed ID: 28682028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.